Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353981 | 0.90 | SIGMAR1 (0.48) | SIGMAR1HRH3GRIN2B | |
| SCHEMBL5353726 | 0.90 | GRIN2B (0.50) | SIGMAR1HRH3GRIN2B | |
| SCHEMBL5799538 | 0.90 | SIGMAR1 (0.48) | SIGMAR1HRH3GRIN2B | |
| SCHEMBL5356599 | 0.87 | SIGMAR1 (0.46) | SIGMAR1HRH3GRIN2B | |
| SCHEMBL5796501 | 0.87 | SIGMAR1 (0.46) | SIGMAR1HRH3GRIN2B | |
| SCHEMBL5354407 | 0.87 | GRIN2B (0.59) | SIGMAR1HRH3GRIN2B | |
| SCHEMBL5345695 | 0.87 | SIGMAR1 (0.51) | SIGMAR1HRH3GRIN2B | |
| SCHEMBL5778248 | 0.87 | SIGMAR1 (0.51) | SIGMAR1HRH3GRIN2B | |
| SCHEMBL5351992 | 0.87 | SIGMAR1 (0.59) | SIGMAR1HRH3GRIN2B | |
| SCHEMBL5366030 | 0.87 | SIGMAR1 (0.51) | SIGMAR1HRH3GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858882-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2007-11-28 | — | — | EP | disclosed |
| US-7217716-B2 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217716-B2 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217716-B2 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
| WO-2006099231-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
| US-7053089-B2 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK & CO., INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1379520-B1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20040209889-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME CORP. | 2004-10-21 | — | — | US | disclosed |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK SHARP & DOHME LLC | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209889-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | GRIN1, GRIN2B, GRIN2A | VNN1 3403/4885SIGMAR1 41/4885HRH3 503/4885 |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | GRIN1, GRIN2B, GRIN2A | VNN1 3372/4885SIGMAR1 41/4885HRH3 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.